Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Akebia Therapeutics (AKBA)
Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,698
  • Shares Outstanding, K 184,248
  • Annual Sales, $ 292,600 K
  • Annual Income, $ -92,560 K
  • 60-Month Beta 0.84
  • Price/Sales 0.43
  • Price/Cash Flow N/A
  • Price/Book 13.50
Trade AKBA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.44
  • Most Recent Earnings -0.04 on 03/09/23
  • Next Earnings Date 05/08/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 505.57% ( +505.57%)
  • Historical Volatility 168.60%
  • IV Percentile 93%
  • IV Rank 39.32%
  • IV High 1,237.65% on 01/19/23
  • IV Low 31.10% on 08/16/22
  • Put/Call Vol Ratio 0.10
  • Today's Volume 138
  • Volume Avg (30-Day) 687
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 33,133
  • Open Int (30-Day) 37,520

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.16
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6120 +4.38%
on 03/15/23
1.0800 -40.85%
on 03/08/23
-0.1865 (-22.60%)
since 02/24/23
3-Month
0.4088 +56.26%
on 12/28/22
1.2000 -46.77%
on 02/08/23
+0.2121 (+49.71%)
since 12/23/22
52-Week
0.2410 +165.06%
on 10/24/22
2.6000 -75.43%
on 03/28/22
-1.8612 (-74.45%)
since 03/24/22

Most Recent Stories

More News
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.6388 (-6.80%)
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 71.43% and 14.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AKBA : 0.6388 (-6.80%)
HRTX : 1.9050 (-7.75%)
Akebia Therapeutics: Q4 Earnings Snapshot

Akebia Therapeutics: Q4 Earnings Snapshot

AKBA : 0.6388 (-6.80%)
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.6388 (-6.80%)
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates

Plus (PSTV) delivered earnings and revenue surprises of -6.67% and 88.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PSTV : 0.2675 (-2.44%)
AKBA : 0.6388 (-6.80%)
Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

/PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ: AKBA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...

AKBA : 0.6388 (-6.80%)
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.6388 (-6.80%)
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

AZN : 67.91 (+0.97%)
GSK : 34.38 (-2.39%)
AKBA : 0.6388 (-6.80%)
FGEN : 18.15 (-2.79%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.6388 (-6.80%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.6388 (-6.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 0.7585
2nd Resistance Point 0.7243
1st Resistance Point 0.6815
Last Price 0.6388
1st Support Level 0.6045
2nd Support Level 0.5703
3rd Support Level 0.5275

See More

52-Week High 2.6000
Fibonacci 61.8% 1.6989
Fibonacci 50% 1.4205
Fibonacci 38.2% 1.1421
Last Price 0.6388
52-Week Low 0.2410

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar